PTC/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

r the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 4

Co	inpiete ii Known
Application Number	10/550,661
Filing Date	September 26, 2005
First Named Inventor	Brown
Art Unit	Unknown 1625
Examiner Name	Unknown CovingTon
Attorney Docket Number	101025-1P US 7

Sheet 1 U. S. PATENT DOCUMENTS Name of Petentee or Applicant of Cited Document Document Number Publication Date Pages, Columns, Lines, Where vant Passeges or Relevant Figures Appear Number-Kind Code^{2 (Farese)} US- 2.898,339 08-04-1959 Wheeler et al. ^{US-} 4,581,171 04-08-1986 Kennis et al. US- 4,816,586 03-28-1989 Portoghese US- 4,939,137 07-03-1990 Russell et al us- 5,140,029 08-18-1992 Kennis et al. US- 5,574,159 11-12-1996 Chang et al. US- 5,683,998 11-04-1997 Shibayama et al. US- 6,187,792 02-13-2001 Delarme et al US- 6,455,545 09-24-2002 Delorme et al. us- 6,552,036 04-22-2003 Boyd et al. us- 6,556,387 Misso et al. 04-29-2003 us- 6,756,387 06-29-2004 Brown et al. US US-IIS. IIIS. US US-

FOREIGN PATENT DOCUMENTS						
	Cite No.	Foreign Patent Document Publication Date Country Code ¹ Number ⁴ 'Kind Code ⁴ (# known)		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
				Or Relevant Figures Appear		
Ke-		WO 93/15062	08-05-1993	The Wellcome Foundation		Г
6		WO 97/23466	07-03-1997	Astra Aktiebolag		Г
4		WO 98/28275	07-02-1998	Astra Pharma Inc,		Ε
N		WO 99/33806	07-08-1999	Ortho-McNeil Pharmaceutic		Г
'b		WO 01/74804	10-11-2001	AstraZeneca AB		Г
7.		WO 01/74806	10-11-2001	AstraZeneca AB		Г

Earnines | Date | Considered | Date the appropriate symbols as indicated on the doc Trenslation is attached.

Translation is alladed.
Transl

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

JAN 0 9 7006 Start a THE

(Usa as many sheets as necessary)

Filing Date September 26, 2005 First Named Inventor Brown Art Unit Unknews /625 Examiner Name 101025-1P US Attorney Docket Number

Examiner	Cite	Document Number	Publication Data	Nama of Patentee or	Pages, Columns, Lines, Where		
Initials*	Cite No.1	Number-Kind Code ^{2 (Florent)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
		US-					
	$\overline{}$	US-					
		US-					
		US-					
		US-					
		US-					
	_	US-	1		1		
	_	US-	1		 		
	_	US-			·		
	_	US-	1				
		US-	i				
		US-					
		US-	1				
		US-					
		US-					
		US-	1				
		US-	1				
	-	US-	1				
		US-					

FOREIGN PATENT DOCUMENTS							
Examiner tritlels*	Cits Foreign Patent Document No.* Country Code* "Number * 'Kind Code* (if Anown)		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		MM-DD-YYYY		Or Relevant Figures Appear			
Xe.		WO 02/094782	11-28-2002	AstraZeneca AB			
4		WO 02/094783	11-28-2002	AstraZeneca AB			
16		WO 02/094784	11-28-2002	AstraZeneca AB		Ε	
D		WO 02/094785	11-28-2002	AstraZeneca AB		С	
40	l	WO 02/094786	11-28-2002	AstraZeneca AB			
ito		WO 02/094812	11-28-2002	AstraZeneca AB		Г	

Examine | Determine | Deservation | Deservat

Translation is allabeled.

In inspired by 37 CPR 197 and 198. The Information is registed to obtain or retain a benefit by the public public in the last of the good by the USPTO to proceed an application. Certificated byte in proceedings by governed by \$5 U.S.C. 122 and 37 CPR 11.4 The Condection is estimated to bits 2 cours to consider the inspired byte interesting in proceedings in the proceedings of the USPTO. Three will very depending upon the individual case. Any comments on the amount of their good required to proceedings to the amount of their good required to proceedings to the source of their source of the source of their source of their

JAN. 0 9 7006

PTC/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patant and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRACEMENT Substitute for form 1449/PTO the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 4

Application Number 10/550,661 Filing Date September 26, 2005 First Named Inventor Brown Examiner Name Unknown Coverage Atterney Docket Number 101025-TP US

Sheet 3 U. S. PATENT DOCUMENTS Document Number Publication Data MM-DD-YYYY Pages, Columns, Lines, Where Relevent Passages or Ralevent Figures Appear Applicant of Cited Document Number-Kind Code^{2 (F known)} US-US US US US-US US-US US-US US-US-US-US-US-US-US-

Exeminer Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Petentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Ralevant Figures Appear	74
		Country Code ³ Number ⁴ Kind Code ⁴ (# known)	MM-DD-YYYY			
14		WO 03/029215	04-10-2003	AstraZeneca AB		
					1	L
						L
	-					Ļ
	-					L
					l	L

Examinar Speature Considered Date Considered D

Trinsation is etached.

In surgical by 37 CPR 197 and 188. The information is required to obtain or stain in brainfly this public which is his fast by the USPTO in processing an application. Confidentiality is governed by \$8 U.S.C. 122 and 37 CPR 11.4 The Confederior is estimated to last 2 cours to complex including glathering, presenting, and submitting the completed application form to the USPTO. These will vary depending upon the inclinitial scale. Any comments on the amount of these upon explore to professing pages from the reducing the brainer, should be sent to the CDR Information Collinium (3. Pelant TDC. Commissioner for Patients, P.O. Box 1489, Alexandris, VA 2213-1450.

TO: Commissioner for Patients, P.O. Box 1489, Alexandris, VA 2213-1450.

TO: Commissioner for Patients, P.O. Box 1489, Alexandris, VA 2213-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006, OMB 0651-0331
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TENT & TRACE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a velid OMB control num

Complete if Known Application Number 10/550,661 INFORMATION DISCLOSURE Fillng Date September 26, 2005 STATEMENT BY APPLICANT First Named Inventor Brown Art Unit Unknows 1625 (Usa as many sheets as necessary) Examiner Name Covinator Attorney Docket Number of 4 101025-1P US

JAN 0 9 7006

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
R		BARBER, A. et al., "Antinociceptive effects of the 5-HT2 Antagonist Ritanserin in Rats: Evidence in the Spinal Cord," Neuroscience Letters, 1989, Vol. 99, pgs 234-238	
þ		BILSKY, E. et al., "SNC 80, A Selective, Nonpeptidic and Systematically Active Opioid Delta Agonist," J. Pharmacology Experimental Ther., 1995, Vol. 273, pgs. 359-366	
R		GREENE T., "Protective Groups in Organic Synthesis," Wiley & Sons, 1982, pgs. 218, 220, 232, 233, 251	
K		TAKEMORI, A.E. et al., "Selective Natrexone-Derived Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol., 1992, Vol. 32, pgs. 239-269	
k		WEI, Z. et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide A Novel and its Analogues," J. Med. Chem., 2000, Vol. 43, pgs. 3895-3905	
/L		ZHANG, X. et al., "Probes for Narcolic Receptor Mediated Phenomena. 28. 1-3 Synthesis Opioid Receptor Ligands, J. Med. Chem., 1999, Vol. 42, pgs. 5455-5463	

Signature Leur	rand Carrie to	Date Considered	61	13/0	d
	ce considered, whether o not citation is in confi	rmance with MPEP 609. Draw line through o	itation if n	ot in confor	mance and not

considered, include copy of this form with next commissionation to applicate.

The control of the copy of the form with next commissionation to applicate a relative term of English terrogates. Transition is subcred.

This collection of thermation is a subcred by 20 CFF 1.81. The information is regulated to obtain or trains a benefit by the positive which is to life (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to Lake 2 hours to complish, choosing a general control on the USPTO. Then will very deponding upon the individual cases. Any commission on the process of the control of the CFF 1.25 CFF 1.25